{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:38:38Z","timestamp":1769755118732,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xi\u2019an Science and Technology Project","award":["20YXYJ0008(3))"],"award-info":[{"award-number":["20YXYJ0008(3))"]}]},{"name":"Key Research and Development Program of Shaanxi Province, China","award":["2020SF-26"],"award-info":[{"award-number":["2020SF-26"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770936"],"award-info":[{"award-number":["81770936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the influence of age on the function and morphology of patients with myopic choroidal neovascularization (mCNV) and to evaluate the effect and prognostic factors of recurrence of Conbercept treatment on mCNV patients over 50\u00a0years. A total of 64 patients (64 eyes) with mCNV were enrolled in this retrospective study. The differences in baseline best-corrected visual acuity (BCVA) and morphological features on imaging between the younger group (\u02c2\u00a050\u00a0years) and the older group (\u2265\u200950\u00a0years) were analyzed. Of all, 21 eyes of 21 mCNV patients aged over 50\u00a0years who received Conbercept injection were further analyzed. Between the younger and the older group, significant differences were shown in mean BCVA (0.58\u2009\u00b1\u20090.28 vs 0.77\u2009\u00b1\u20090.31), subfoveal choroidal thickness (SFCT) (108.17\u2009\u00b1\u200978.32\u00a0\u03bcm vs 54.68\u2009\u00b1\u200939.03\u00a0\u03bcm) and frequency of vitreoretinal interface abnormalities (VIA) (2 vs 13), respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). After treated with Conbercept, the mean BCVA of 21 older mCNV patients increased from 0.83\u2009\u00b1\u20090.30 at baseline to 0.49\u2009\u00b1\u20090.24 at one year. Baseline BCVA, external limiting membrane damage, CNV area and CNV location correlated with the visual acuity at the 1-year follow-up. There were 7 (33.3%) recurrent cases during the follow-up and the risk of recurrence in patients with baseline central macular thickness (CMT)\u2009\u2265\u2009262.86\u00a0\u03bcm was 14 times greater than that of patients with CMT\u2009&lt;\u2009262.86\u00a0\u03bcm. The risk of recurrence increased 1.84 times for every 100-\u03bcm increment in the CMT. Patients over 50\u00a0years with mCNV had a worse BCVA, thinner choroid, and higher risk of VIA than young mCNV patients. The standard Conbercept treatment strategy was safe and effective in mCNV patients over 50\u00a0years. As patients over 50\u00a0years with a greater CMT have a high risk of recurrence, more attention should be paid on these patients by following them up closely.<\/jats:p>","DOI":"10.1038\/s41598-021-86835-6","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:03:08Z","timestamp":1617271388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Baseline characteristics of myopic choroidal neovascularization in patients above 50\u00a0years old and prognostic factors after intravitreal conbercept treatment"],"prefix":"10.1038","volume":"11","author":[{"given":"Hai-Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Zhang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"86835_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong, T. Y., Ferreira, A., Hughes, R., Carter, G. & Mitchell, P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am. J. Ophthalmol. 157, 9\u201325 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"86835_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden, B. A. et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123, 1036\u20131042 (2016).","journal-title":"Ophthalmology"},{"key":"86835_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1025488429802","volume":"24","author":"F Bottoni","year":"2001","unstructured":"Bottoni, F. & Tilanus, M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int. Ophthalmol. 24, 249\u2013255 (2001).","journal-title":"Int. Ophthalmol."},{"key":"86835_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","volume":"243","author":"K Hayashi","year":"2005","unstructured":"Hayashi, K. et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 243, 13\u201319 (2005).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"86835_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/eye.2009.88","volume":"23","author":"JM Mones","year":"2009","unstructured":"Mones, J. M., Amselem, L., Serrano, A., Garcia, M. & Hijano, M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond.) 23, 1275\u20131281 (2009).","journal-title":"Eye (Lond.)"},{"key":"86835_CR6","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","volume":"120","author":"JM Ruiz-Moreno","year":"2013","unstructured":"Ruiz-Moreno, J. M., L\u00f3pez-G\u00e1lvez, M. I., Moreno, J. A. M. & Jimeno, J. C. P. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. Ophthalmology 120, 1510\u20131511 (2013).","journal-title":"Ophthalmology"},{"key":"86835_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf, S. et al. RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121, 682\u2013692 (2014).","journal-title":"Ophthalmology"},{"key":"86835_CR8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno, Y. et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study. Ophthalmology 122, 1220\u20131227 (2015).","journal-title":"Ophthalmology"},{"key":"86835_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","volume":"109","author":"T Yoshida","year":"2002","unstructured":"Yoshida, T. et al. Long-term visual prognosis of choroidal neovascularization in high myopia: A comparison between age groups. Ophthalmology 109, 712\u2013719 (2002).","journal-title":"Ophthalmology"},{"key":"86835_CR10","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0161-6420(99)90484-0","volume":"106","author":"H Tabandeh","year":"1999","unstructured":"Tabandeh, H. et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106, 2063\u20132067 (1999).","journal-title":"Ophthalmology"},{"key":"86835_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/IAE.0000000000002237","volume":"39","author":"S Gattoussi","year":"2019","unstructured":"Gattoussi, S. et al. Choroidal thickness, vascular factors, and age-related macular degeneration: The ALIENOR study. Retina 39, 34\u201343 (2019).","journal-title":"Retina"},{"key":"86835_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/eye.2016.216","volume":"31","author":"KR Chirco","year":"2017","unstructured":"Chirco, K. R., Sohn, E. H., Stone, E. M., Tucker, B. A. & Mullins, R. F. Structural and molecular changes in the aging choroid: implications for age-related macular degeneration. Eye (Lond.) 31, 10\u201325 (2017).","journal-title":"Eye (Lond.)"},{"key":"86835_CR13","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1111\/aos.12117","volume":"91","author":"CMG Cheung","year":"2013","unstructured":"Cheung, C. M. G. et al. Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization. Acta. Ophthalmol. 91, e580\u2013e581 (2013).","journal-title":"Acta. Ophthalmol."},{"key":"86835_CR14","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1167\/iovs.09-3493","volume":"51","author":"Y Ikuno","year":"2010","unstructured":"Ikuno, Y., Jo, Y., Hamasaki, T. & Tano, Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest. Ophth. Vis. Sci. 51, 3721\u20133725 (2010).","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"86835_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/bjophthalmol-2015-307050","volume":"99","author":"H Ye","year":"2015","unstructured":"Ye, H. et al. Prevalence and associations of epiretinal membrane in an elderly urban Chinese population in China: the Jiangning eye study. Br. J. Ophthalmol. 99, 1594\u20131597 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"86835_CR16","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1167\/iovs.08-2624","volume":"50","author":"XR Duan","year":"2009","unstructured":"Duan, X. R. et al. Prevalence and associations of epiretinal membranes in a rural Chinese adult population: the Handan eye study. Invest. Ophthalmol. Vis. Sci. 50, 2018\u20132023 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"86835_CR17","doi-asserted-by":"crossref","unstructured":"Hashemi, S., Faramarzi, M. A., Ghasemi, Falavarjani, K. & Abdollahi, M. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opin. Biol. Ther. 14, 1837\u20131848 (2014).","DOI":"10.1517\/14712598.2014.967210"},{"key":"86835_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/IAE.0000000000000684","volume":"36","author":"M Battaglia Parodi","year":"2016","unstructured":"Battaglia Parodi, M., Iacono, P. & Bandello, F. Correspondence of leakage on fluorescein angiography and optical coherence tomography parameters in diagnosis and monitoring of myopic choroidal neovascularization treated with bevacizumab. Retina 36, 104\u2013109 (2016).","journal-title":"Retina"},{"key":"86835_CR19","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1167\/iovs.17-23640","volume":"59","author":"M Battaglia Parodi","year":"2018","unstructured":"Battaglia Parodi, M., Iacono, P., Romano, F. & Bandello, F. Fluorescein leakage and optical coherence tomography features of choroidal neovascularization secondary to pathologic myopia. Invest. Ophthalmol. Vis. Sci. 59, 3175\u20133180 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"86835_CR20","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00417-018-4060-3","volume":"256","author":"X Ding","year":"2018","unstructured":"Ding, X. et al. Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: Correlation with activity. Graefes Arch. Clin. Exp. Ophthalmol. 256, 1831\u20131837 (2018).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"86835_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00417-017-3706-x","volume":"255","author":"P Milani","year":"2017","unstructured":"Milani, P. et al. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?. Graefes Arch. Clin. Exp. Ophthalmol. 255, 1713\u20131720 (2017).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"86835_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3928\/23258160-20170329-07","volume":"48","author":"S Zandi","year":"2017","unstructured":"Zandi, S. et al. Pre-existing RPE atrophy and defects in the external limiting membrane predict early poor visual response to ranibizumab in neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging Retina. 48, 326\u2013332 (2017).","journal-title":"Ophthalmic. Surg. Lasers Imaging Retina."},{"key":"86835_CR23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","volume":"31","author":"JZ Kuo","year":"2011","unstructured":"Kuo, J. Z. et al. Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization. Retina 31, 1835\u20131840 (2011).","journal-title":"Retina"},{"key":"86835_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/eye.2010.226","volume":"25","author":"H Nakanishi","year":"2011","unstructured":"Nakanishi, H. et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye 25, 375\u2013381 (2011).","journal-title":"Eye"},{"key":"86835_CR25","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","volume":"156","author":"HS Yang","year":"2013","unstructured":"Yang, H. S., Kim, J., Kim, J. T. & Joe, S. G. Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am. J. Ophthalmol. 156, 1201\u20131210 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"86835_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ceo.13424","volume":"47","author":"S Li","year":"2019","unstructured":"Li, S. et al. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. Clin. Exp. Ophthalmol. 47, 250\u2013258 (2019).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"86835_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000458160","volume":"237","author":"BG Moon","year":"2017","unstructured":"Moon, B. G. et al. Improved visual outcome and low recurrence with early treatment with intravitreal anti-vascular endothelial growth factor in myopic choroidal neovascularization. Ophthalmologica 237, 128\u2013138 (2017).","journal-title":"Ophthalmologica"},{"key":"86835_CR28","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","volume":"35","author":"DS Ng","year":"2015","unstructured":"Ng, D. S., Kwok, A. K., Tong, J. M., Chan, C. W. & Li, W. W. Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina 35, 2457\u20132468 (2015).","journal-title":"Retina"},{"key":"86835_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/eye.2011.94","volume":"25","author":"YM Kim","year":"2011","unstructured":"Kim, Y. M., Yoon, J. U. & Koh, H. J. The analysis of lacquer crack in the assessment of myopic choroidal neovascularization. Eye (Lond). 25, 937\u2013946 (2011).","journal-title":"Eye (Lond)."},{"key":"86835_CR30","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","volume":"33","author":"HM Kang","year":"2013","unstructured":"Kang, H. M. & Koh, H. J. Ocular risk factors for recurrence of myopic choroidal neovascularization: Long-term follow-up study. Retina 33, 1613\u20131622 (2013).","journal-title":"Retina"},{"key":"86835_CR31","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1167\/iovs.12-11542","volume":"54","author":"SJ Ahn","year":"2013","unstructured":"Ahn, S. J., Woo, S. J., Kim, K. E. & Park, K. H. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Invest. Ophth. Vis. Sci. 54, 2115\u20132122 (2013).","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"86835_CR32","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1167\/iovs.14-16006","volume":"56","author":"SJ Ahn","year":"2015","unstructured":"Ahn, S. J., Park, K. H. & Woo, S. J. Subfoveal choroidal thickness changes following anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 56, 5794\u20135800 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"86835_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.survophthal.2016.02.007","volume":"61","author":"KA Tan","year":"2016","unstructured":"Tan, K. A. et al. State of science: Choroidal thickness and systemic health. Surv. Ophthalmol. 61, 566\u2013581 (2016).","journal-title":"Surv. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86835-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86835-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:18:54Z","timestamp":1670048334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86835-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86835"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86835-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7337"}}